Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry Hancock

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
The New England Journal of Medicine|April 23, 2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphomaJohn Radford, Tim Illidge, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID StudySally F Barrington, Elizabeth H Phillips, Nicholas Counsell, et al.
Lancet (London, England)|February 16, 2010
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trialMartin E Gore, Clare L Griffin, Barry Hancock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell CancerBhavna Oza, Tim Eisen, Eleni Frangou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup TrialTim Eisen, Eleni Frangou, Bhavna Oza, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
The New England Journal of Medicine|April 23, 2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphomaJohn Radford, Tim Illidge, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2019
Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID StudySally F Barrington, Elizabeth H Phillips, Nicholas Counsell, et al.
Lancet (London, England)|February 16, 2010
Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trialMartin E Gore, Clare L Griffin, Barry Hancock, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 25, 2022
External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell CancerBhavna Oza, Tim Eisen, Eleni Frangou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2020
Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup TrialTim Eisen, Eleni Frangou, Bhavna Oza, et al.
Pageof 3